Hunter C Smith Rhythm Pharmaceuticals, Inc. (RYTM) insider trading activity

Hunter C Smith is Chief Financial Officer of RHYTHM PHARMACEUTICALS, INC.. Currently has a direct ownership of 97,939 shares of RYTM, which is worth approximately $5.54 Million. The most recent transaction as insider was on Mar 19, 2024, when has been sold 15,515 shares (Common Stock) at a price of $39.22 per share, resulting in proceeds of $608,498. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 97.9K

0% 3M change

59.49% 12M change

Total Value Held $5.54 Million

Hunter C Smith Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 19 2024	SELL Open market or private sale	$608,498 $39.22 p/Share	15,515 Reduced 13.68%	97,939 Common Stock
Feb 16 2024	BUY Grant, award, or other acquisition	-	33,750 Added 22.93%	113,454 Common Stock
Feb 13 2024	SELL Open market or private sale	$35,322 $49.82 p/Share	709 Reduced 0.88%	79,704 Common Stock
Feb 12 2024	SELL Open market or private sale	$62,118 $51.38 p/Share	1,209 Reduced 1.48%	80,413 Common Stock
Feb 11 2024	BUY Exercise of conversion of derivative security	-	2,344 Added 2.79%	81,622 Common Stock
Feb 09 2024	BUY Exercise of conversion of derivative security	-	4,063 Added 4.88%	79,278 Common Stock
Feb 01 2024	SELL Open market or private sale	$72,816 $45.06 p/Share	1,616 Reduced 2.1%	75,215 Common Stock
Feb 01 2024	BUY Exercise of conversion of derivative security	-	4,925 Added 6.02%	76,831 Common Stock
Dec 29 2023	BUY Exercise of conversion of derivative security	$72,240 $6.88 p/Share	10,500 Added 12.74%	71,906 Common Stock
Dec 06 2023	SELL Open market or private sale	$800,000 $40.0 p/Share	20,000 Reduced 24.57%	61,406 Common Stock
Dec 06 2023	BUY Exercise of conversion of derivative security	$137,600 $6.88 p/Share	20,000 Added 19.72%	81,406 Common Stock
Dec 05 2023	SELL Open market or private sale	$246,331 $35.06 p/Share	7,026 Reduced 10.27%	61,406 Common Stock
Dec 05 2023	BUY Exercise of conversion of derivative security	$48,338 $6.88 p/Share	7,026 Added 9.31%	68,432 Common Stock
Nov 24 2023	SELL Open market or private sale	$384,309 $35.02 p/Share	10,974 Reduced 15.16%	61,406 Common Stock
Nov 24 2023	BUY Exercise of conversion of derivative security	$75,501 $6.88 p/Share	10,974 Added 13.17%	72,380 Common Stock
Nov 14 2023	SELL Open market or private sale	$364,560 $30.38 p/Share	12,000 Reduced 16.35%	61,406 Common Stock
Nov 14 2023	BUY Exercise of conversion of derivative security	$82,560 $6.88 p/Share	12,000 Added 14.05%	73,406 Common Stock
Jun 16 2023	BUY Exercise of conversion of derivative security	$13,760 $6.88 p/Share	2,000 Added 3.15%	61,406 Common Stock
Feb 14 2023	SELL Open market or private sale	$18,862 $26.87 p/Share	702 Reduced 1.17%	59,406 Common Stock
Feb 11 2023	BUY Exercise of conversion of derivative security	-	2,344 Added 3.75%	60,108 Common Stock
Feb 09 2023	SELL Open market or private sale	$38,668 $27.66 p/Share	1,398 Reduced 2.36%	57,779 Common Stock
Feb 09 2023	BUY Exercise of conversion of derivative security	-	4,063 Added 6.42%	59,177 Common Stock
Dec 23 2022	SELL Bona fide gift	-	2,500 Reduced 4.34%	55,114 Common Stock
Jul 01 2022	SELL Open market or private sale	$30,792 $4.08 p/Share	7,547 Reduced 11.58%	57,614 Common Stock
Jun 30 2022	BUY Exercise of conversion of derivative security	-	25,000 Added 27.73%	65,161 Common Stock

Also insider at

AGLE

Aeglea BioTherapeutics, Inc. Healthcare

Director

HCS

Hunter C Smith

Chief Financial Officer

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RYTM shares.

Notify only if

Value

Insider Trading

Get notified when an Rhythm Pharmaceuticals, Inc. insider buys or sells RYTM shares.

Notify only if

Operation

Value

Type

News

Receive news related to RHYTHM PHARMACEUTICALS, INC.

Track Activities on RYTM

Account